01 Growing Transition Toward Gene and Cell Therapies for Rare Diseases The rare disease treatment market is witnessing a shift from symptomatic disease management toward gene and cell therapies that target the underlying genetic causes of rare disorders. This transition is improving the potential for long-term clinical benefits while reducing the need for lifelong treatment in certain conditions. For example, CASGEVY represents a significant advancement in gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia.
02 Increasing Integration of Artificial Intelligence in Rare Disease Diagnosis The market is experiencing growing adoption of artificial intelligence to improve the identification and diagnosis of rare diseases, addressing challenges associated with delayed or inaccurate diagnoses. AI-powered analytics help clinicians interpret genetic data, detect disease patterns, and identify eligible patients more efficiently. This transition is supporting earlier treatment initiation, improved clinical decision-making, and better patient outcomes. For example, Mendelian uses AI-driven patient identification technology to help healthcare providers detect individuals with undiagnosed rare genetic disorders from electronic health records.
01 The rare disease treatment market has moderate to high exposure to supply chain disruptions due to its dependence on complex biologics, specialized raw materials, cold-chain logistics, and limited manufacturing facilities. Disruptions in the supply of active pharmaceutical ingredients, specialized packaging materials, and transportation networks can delay production, regulatory approvals, and timely patient access to life-saving therapies across global markets. The market is demonstrating a capacity-constrained recovery, supported by supply chain diversification, regional manufacturing expansion, strategic inventory management, and continued investments in resilient production networks.
01 The rare disease treatment market forecasts continued investment activity driven by rapid advances in gene and cell therapies, expanding orphan drug development, and increasing demand for precision medicine.
02 Key Investment and Funding Activities in Rare Disease Treatment Market, 2025–2026 Company Funding/Investment (USD) Details Scribe Therapeutics USD 128.7 million (IPO) In July 2026, Scribe Therapeutics raised approximately USD 128.7 million through its initial public offering to advance its genetic medicines pipeline and expand clinical development capabilities. Sarepta Therapeutics USD 174 million In August 2025, Sarepta Therapeutics generated USD 174 million through the sale of its Arrowhead Pharmaceuticals equity investment, strengthening liquidity to support its rare disease pipeline and strategic priorities.
01 Increasing Orphan Drug Incentives and Expansion of Genetic and Newborn Screening Programs Drives Market Favorable orphan drug policies and regulatory incentives are driving the development and commercialization of therapies for rare diseases, increasing the availability of innovative treatment options. Benefits such as market exclusivity, tax credits, fee reductions, and accelerated review pathways encourage pharmaceutical and biotechnology companies to invest in rare disease research. This strengthens product pipelines and improves patient access to advanced therapies. For example, the US FDA's Orphan Drug Designation program and the European Medicines Agency's orphan medicine incentives continue to support the launch of novel rare disease treatments, driving market growth.The growing implementation of national genetic and newborn screening programs is increasing the identification of rare diseases at earlier stages, creating a larger diagnosed patient pool requiring treatment. Earlier diagnosis enables timely therapeutic intervention, improving long-term clinical outcomes while increasing demand for orphan drugs and advanced therapies. For example, the US Recommended Uniform Screening Panel and expanded newborn screening programs across Europe are identifying more patients eligible for early rare disease treatment, driving market growth.
01 Small Patient Populations and High Cost of Advanced Rare Disease Therapies Restrain Market Expansion Rare diseases affect small patient populations, making it difficult to recruit enough participants for clinical trials. Limited patient availability extends trial timelines, increases research and development costs, and complicates the generation of robust clinical evidence required for regulatory approval.Gene therapies, enzyme replacement therapies, and other advanced biologics require complex manufacturing processes and specialized delivery, resulting in exceptionally high treatment costs. These costs create reimbursement challenges and limit patient access, particularly in low- and middle-income countries where healthcare budgets are constrained.
01 Increasing Development of RNA-based Therapies and Expansion of Rare Disease Centers of Excellence Offer Growth Opportunities to Market Players Advancements in RNA-based therapeutics, including antisense oligonucleotides and RNA interference (RNAi), are creating new opportunities for biotechnology and pharmaceutical companies to treat previously undruggable rare diseases. These platforms enable highly targeted therapies with the potential to address a wider range of genetic disorders and expand future product pipelines. As clinical success and regulatory approvals increase, investments in RNA technologies are expected to accelerate. Companies such as Ionis Pharmaceuticals, Alnylam Pharmaceuticals, and Novo Nordisk are actively expanding their rare disease portfolios through RNA-based innovations.The increasing establishment of dedicated rare disease centers of excellence is creating new opportunities for pharmaceutical companies, specialty healthcare providers, and contract service organizations. These centers improve multidisciplinary care, facilitate patient referrals, and enable faster adoption of advanced therapies through specialized clinical expertise. As countries continue investing in national rare disease networks and cross-border treatment collaborations, access to orphan drugs is expected to expand significantly.
01 Fragmented Rare Disease Diagnostic Pathways and Scaling Individualized Manufacturing Challenges Market Growth Rare disease patients often undergo multiple referrals across geneticists, neurologists, metabolic specialists, and tertiary care centers before receiving treatment, creating fragmented care pathways. This delays therapy initiation, reduces the number of eligible patients reaching specialized treatment centers, and slows commercial uptake of newly approved therapies.The growing adoption of personalized gene-editing and patient-specific therapies is increasing operational complexity for manufacturers. Each treatment batch requires individualized production, rigorous quality testing, and coordinated logistics, limiting manufacturing scalability and extending delivery timelines.
July 2026 Ipsen announced the acquisition of Memo Therapeutics, expanding its rare disease portfolio with an investigational therapy for BK polyomavirus-associated nephropathy.
April 2026 Chiesi Group announced the acquisition of KalVista Pharmaceuticals for approximately USD 1.9 billion.
April 2026 Shionogi & Co., Ltd. completed the acquisition of all global rights to RADICAVA (edaravone) from Tanabe Pharma.
March 2026 Biogen Inc. announced the acquisition of Apellis Pharmaceuticals for approximately USD 5.6 billion.
August 2025 Arrowhead Pharmaceuticals and Novartis entered an exclusive global licensing and collaboration agreement to co-develop and commercialize multiple RNAi therapies for rare genetic diseases.